{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:13Z","timestamp":1788480553699,"version":"build-2803163510"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union - Next Generation EU","award":["PNRR-MCNT2-2023-12376978 \u2013 CUP B63C24000460001"],"award-info":[{"award-number":["PNRR-MCNT2-2023-12376978 \u2013 CUP B63C24000460001"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disorder that predisposes affected individuals, especially young patients, to malignant arrhythmias, sudden cardiac death, and heart failure. The disease is characterized by myocardial atrophy and fibro-fatty replacement, predominantly affecting the right ventricle. Current pharmacological treatments primarily aim to alleviate symptoms by addressing arrhythmias and heart failure. These approaches are often complemented by invasive interventions such as implantable cardioverter defibrillators (ICDs) and radiofrequency ablations. However, none of these strategies effectively halts disease progression, highlighting the urgent need for novel disease-modifying therapies. We recently demonstrated that elevated plasma levels of oxidized low-density lipoprotein (oxLDL) correlate with more advanced stages of ACM in patients. Moreover, treatment with atorvastatin, which reduces oxLDL levels, prevented disease manifestation in a mouse model of ACM. Based on these findings, we hypothesize that statins may attenuate disease progression in ACM patients not only through their lipid-lowering effects, but also via pleiotropic actions such as antioxidant, anti-inflammatory, and autonomic modulation. To test this hypothesis, we designed SEARCH (Statin Effect on ARrhythmogenic CardiomyopatHy), an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial, aimed at evaluating the efficacy of atorvastatin in preventing ACM progression (NCT06922994). A total of 102 patients meeting ACM diagnostic criteria will be enrolled and randomized in a 1:1 ratio to receive either atorvastatin 80\u2009mg\/die or placebo for 18 months. The primary outcome will be the change in right ventricular global longitudinal strain, a sensitive echocardiographic measure of ventricular function, from baseline to 18 months. Secondary outcomes will include changes in arrhythmic burden, electrocardiography parameters, additional structural and functional cardiac indices, and circulating biomarkers. Tertiary and exploratory outcomes include the validation of risk scores for ACM progression and the identification of variables predicting the best responders to atorvastatin. Participants will undergo a comprehensive evaluation at baseline, 9 months, and 18 months, including cardiology visits, echocardiography, electrocardiography, blood testing, ICD or loop recorder interrogation, and cardiac magnetic resonance imaging (at enrollment and at 18 months only). Additional safety assessments and telephone follow-ups will be conducted throughout the study to monitor treatment adherence and potential adverse events. The SEARCH trial is expected to generate the first clinical evidence on the efficacy of atorvastatin in slowing ACM progression, thereby addressing a major unmet therapeutic need. The findings will shape the design of future large-scale studies and may pave the way for a novel, disease-modifying treatment strategy to improve outcomes and quality of life for patients with ACM.<\/jats:p>","DOI":"10.1371\/journal.pone.0332876","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:22:57Z","timestamp":1759166577000},"page":"e0332876","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Statin effect on arrhythmogenic cardiomyopathy disease progression (SEARCH): Randomized clinical study protocol"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-4051","authenticated-orcid":true,"given":"Elena","family":"Sommariva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Bruttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-5293","authenticated-orcid":true,"given":"Francesco","family":"Cannata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0720-3380","authenticated-orcid":true,"given":"Marco","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Salina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Vettor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Sicuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pizzamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ribatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Maragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carbucicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"DeLuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Omodeo","family":"Sal\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yari","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Barbarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Monda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Frisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gasperetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina D. A.","family":"Corino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Galotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Pompilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pontone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Muratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5322-1742","authenticated-orcid":true,"given":"Michela","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-8313","authenticated-orcid":true,"given":"Claudio","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"7","key":"pone.0332876.ref001","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCRESAHA.117.309345","article-title":"Arrhythmogenic Cardiomyopathy","volume":"121","author":"D Corrado","year":"2017","journal-title":"Circ Res"},{"key":"pone.0332876.ref002","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2020.06.005","article-title":"Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria","volume":"319","author":"D Corrado","year":"2020","journal-title":"Int J Cardiol"},{"issue":"14","key":"pone.0332876.ref003","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/01.CIR.0000143375.93288.82","article-title":"Natural history and risk stratification of arrhythmogenic right ventricular dysplasia\/cardiomyopathy","volume":"110","author":"J-S Hulot","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"pone.0332876.ref004","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.amjcard.2008.06.054","article-title":"Comparison of clinical features of arrhythmogenic right ventricular cardiomyopathy in men versus women","volume":"102","author":"B Bauce","year":"2008","journal-title":"Am J Cardiol"},{"issue":"19","key":"pone.0332876.ref005","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/ehx011","article-title":"Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy\/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome","volume":"38","author":"D Akdis","year":"2017","journal-title":"Eur Heart J"},{"issue":"7","key":"pone.0332876.ref006","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/hrt.2010.193276","article-title":"Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"97","author":"D Corrado","year":"2011","journal-title":"Heart"},{"issue":"12","key":"pone.0332876.ref007","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.107.181423","article-title":"Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation","volume":"115","author":"BJ Maron","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"pone.0332876.ref008","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/euhj.1998.1403","article-title":"Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases","volume":"20","author":"A Tabib","year":"1999","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0332876.ref009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198801213180301","article-title":"Right ventricular cardiomyopathy and sudden death in young people","volume":"318","author":"G Thiene","year":"1988","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0332876.ref010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.4330\/wjc.v6.i12.1234","article-title":"Arrhythmogenic right ventricular cardiomyopathy: From genetics to diagnostic and therapeutic challenges","volume":"6","author":"B Pinamonti","year":"2014","journal-title":"World J Cardiol"},{"issue":"8","key":"pone.0332876.ref011","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3390\/biom12081043","article-title":"Spectrum of Rare and Common Genetic Variants in Arrhythmogenic Cardiomyopathy Patients","volume":"12","author":"M Lippi","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"pone.0332876.ref012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003273","article-title":"International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework","volume":"14","author":"CA James","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"4","key":"pone.0332876.ref013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jmedgenet-2019-106394","article-title":"FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy","volume":"57","author":"F Brun","year":"2020","journal-title":"J Med Genet"},{"issue":"7","key":"pone.0332876.ref014","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/eurheartj\/ehq025","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the Task Force Criteria","volume":"31","author":"FI Marcus","year":"2010","journal-title":"Eur Heart J"},{"key":"pone.0332876.ref015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2020.06.005","article-title":"Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria","volume":"319","author":"D Corrado","year":"2020","journal-title":"Int J Cardiol"},{"issue":"13","key":"pone.0332876.ref016","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/jcm10132750","article-title":"Arrhythmogenic Cardiomyopathy-Current Treatment and Future Options","volume":"10","author":"F Migliore","year":"2021","journal-title":"J Clin Med"},{"key":"pone.0332876.ref017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ajem.2022.12.010","article-title":"Diagnosis and management of arrhythmogenic right ventricular cardiomyopathy","volume":"65","author":"L Alblaihed","year":"2023","journal-title":"Am J Emerg Med"},{"issue":"16","key":"pone.0332876.ref018","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/eurheartj\/ehi341","article-title":"Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations","volume":"26","author":"B Bauce","year":"2005","journal-title":"Eur Heart J"},{"issue":"11","key":"pone.0332876.ref019","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/eurjhf\/hfs119","article-title":"Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy","volume":"14","author":"PA van der Zwaag","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"pone.0332876.ref020","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/jmedgenet-2021-107911","article-title":"Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure","volume":"59","author":"AH Christensen","year":"2022","journal-title":"J Med Genet"},{"issue":"6","key":"pone.0332876.ref021","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.1423","article-title":"High risk of heart failure associated with desmoglein-2 mutations compared to plakophilin-2 mutations in arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"21","author":"A Hermida","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"pone.0332876.ref022","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/CIRCULATIONAHA.119.044934","article-title":"Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"141","author":"ED Smith","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"pone.0332876.ref023","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jacc.2009.11.020","article-title":"Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy","volume":"55","author":"T Xu","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"pone.0332876.ref024","doi-asserted-by":"crossref","first-page":"568535","DOI":"10.3389\/fphys.2020.568535","article-title":"Mechanotransduction and Adrenergic Stimulation in Arrhythmogenic Cardiomyopathy: An Overview of in vitro and in vivo Models","volume":"11","author":"G Beffagna","year":"2020","journal-title":"Front Physiol"},{"issue":"9","key":"pone.0332876.ref025","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/biom12091324","article-title":"Myocarditis-like Episodes in Patients with Arrhythmogenic Cardiomyopathy: A Systematic Review on the So-Called Hot-Phase of the Disease","volume":"12","author":"R Bariani","year":"2022","journal-title":"Biomolecules"},{"issue":"9","key":"pone.0332876.ref026","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114365","article-title":"Oxidized LDL-dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy","volume":"13","author":"E Sommariva","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"5","key":"pone.0332876.ref027","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"JW Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"pone.0332876.ref028","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.2174\/138161212799504803","article-title":"Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials","volume":"18","author":"AS Antonopoulos","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"1","key":"pone.0332876.ref029","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cardiores.2007.02.029","article-title":"Do statins have an antiarrhythmic activity?","volume":"75","author":"MS Kostapanos","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"2","key":"pone.0332876.ref030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10286-015-0274-1","article-title":"The effect of statins on sympathetic activity: a meta-analysis","volume":"25","author":"J Lewandowski","year":"2015","journal-title":"Clin Auton Res"},{"issue":"1","key":"pone.0332876.ref031","doi-asserted-by":"crossref","first-page":"16671","DOI":"10.1038\/s41598-018-35119-7","article-title":"Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells","volume":"8","author":"M Pontremoli","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0332876.ref032","doi-asserted-by":"crossref","first-page":"1426982","DOI":"10.3389\/fphar.2024.1426982","article-title":"Exploiting the anti-fibrotic effects of statins on thoracic aortic aneurysm progression: results from a meta-analysis and experimental data","volume":"15","author":"VA Myasoedova","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0332876.ref033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0332876.ref034","first-page":"5","article-title":"Management of acute coronary syndrome\u00a0: ESC guidelines 2023","volume":"49","author":"M Buske","year":"2024","journal-title":"Herz"},{"key":"pone.0332876.ref035","author":"C Research","year":"2018"},{"key":"pone.0332876.ref036","unstructured":"European Medicines Agency. Lipitor - Referral. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/lipitor. 2025 July 30."},{"issue":"4","key":"pone.0332876.ref037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00011-009-0093-8","article-title":"Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis","volume":"59","author":"A Zhang","year":"2010","journal-title":"Inflamm Res"},{"issue":"1","key":"pone.0332876.ref038","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20080042","article-title":"Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction","volume":"116","author":"C Stumpf","year":"2009","journal-title":"Clin Sci (Lond)"},{"issue":"21","key":"pone.0332876.ref039","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"PM Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"pone.0332876.ref040","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study","volume":"108","author":"S Kinlay","year":"2003","journal-title":"Circulation"},{"key":"pone.0332876.ref041","doi-asserted-by":"crossref","first-page":"784715","DOI":"10.3389\/fcvm.2021.784715","article-title":"Inflammation in the Pathogenesis of Arrhythmogenic Cardiomyopathy: Secondary Event or Active Driver?","volume":"8","author":"V Meraviglia","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"pone.0332876.ref042","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/CS20130332","article-title":"Statins and the autonomic nervous system","volume":"126","author":"PJ Millar","year":"2014","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"pone.0332876.ref043","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients","volume":"92","author":"CB Newman","year":"2003","journal-title":"Am J Cardiol"},{"key":"pone.0332876.ref044","unstructured":"AIFA - Ricerca farmaco. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000044636. 2025 July 30."},{"issue":"11","key":"pone.0332876.ref045","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","article-title":"High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial","volume":"110","author":"S Tsimikas","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"pone.0332876.ref046","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80\u2009mg versus 10\u2009mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"C Newman","year":"2006","journal-title":"Am J Cardiol"},{"issue":"14","key":"pone.0332876.ref047","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"JC LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0332876.ref048","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jacc.2006.05.053","article-title":"Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy","volume":"48","author":"JJ Goldberger","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"pone.0332876.ref049","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015016","article-title":"Right Ventricular Strain Predicts Structural Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"9","author":"N Malik","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"pone.0332876.ref050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/ehjci\/jeae117","article-title":"Right heart strain in arrhythmogenic right ventricular cardiomyopathy: implications for cardiovascular outcome","volume":"25","author":"S Anwer","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"pone.0332876.ref051","first-page":"388","article-title":"Prognostic Value of Strain by Speckle Tracking Echocardiography in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy","volume":"11","author":"A Aljehani","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"key":"pone.0332876.ref052","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jacc.2023.05.065","article-title":"Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum","volume":"82","author":"FP Kirkels","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"pone.0332876.ref053","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2022.21243","article-title":"Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension","volume":"328","author":"NJ Butcher","year":"2022","journal-title":"JAMA"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:23:04Z","timestamp":1759166584000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332876"}},"subtitle":[],"editor":[{"given":"Jen","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332876","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}